New Exposure Limits For Excipients Applauded While Loss Of Old Potency Limits Bemoaned
Executive Summary
The US FDA has launched the second phase of an effort to improve its inactive ingredients database by replacing confusing potency amounts with maximum daily exposure limits, a change sought by generic drug and excipient manufactures.